AmoyDx and Johnson & Johnson Announce Strategic Collaboration on Companion Diagnostics to Support J&J's Oncology Portfolio

Mar 24, 2020 23:06 CST Updated 23:06

Johnson & Johnson

Healthcare Product Manufacturers, Health Service Providers

Shanghai, China – Recently, Amoy Diagnostics (SZSE: 300685) has entered into a strategic partnership for companion diagnostics with the renowned multinational pharmaceutical company Johnson & Johnson. Under the agreement, Amoy Diagnostics will leverage its proprietary NGS technology platform to advance^®Variation registration (approved for market launch by the NMPA on November 20, 2018) to expand the scope of companion diagnostics and support Johnson & Johnson’s oncology product portfolio.

In the field of tumor companion diagnostics, Amoy Diagnostics strictly adheres to national laws and industry standards, has established a comprehensive, multi-technology platform-based overall solution for genetic testing that has gained international recognition, and has formed strategic partnerships with renowned multinational pharmaceutical companies including AstraZeneca, Pfizer, Merck, Boehringer Ingelheim, Eli Lilly, and Eisai.

The development of precision medicine necessitates the co-development of targeted therapies and companion diagnostics, fostering deep collaboration between pharmaceutical companies and companion diagnostic enterprises. With outstanding innovation, R&D, and industrialization capabilities, a robust quality management and assurance system, and extensive experience in clinical development and regulatory approval of companion diagnostics, Amoy Diagnostics has become the preferred partner for leading domestic and international pharmaceutical companies in developing companion diagnostics for blockbuster targeted drugs. Previously, Amoy Diagnostics’ ROS1 assay supported Pfizer’s pan-Asia-Pacific clinical study of the targeted therapy crizotinib (Xalkori), facilitating its market approval and inclusion in the national reimbursement drug lists in Japan and South Korea, as well as in Taiwan, China. In June 2019, AiHuiJian^®He Wei Hui Jian^®Served as the companion diagnostic reagent for Eli Lilly’s RET inhibitor LOXO-292 in Asian clinical trials; in November 2019, Amoy Diagnostics entered into a collaboration with Eisai Co., Ltd. of Japan on the development and registration of companion diagnostics for its emerging targeted therapies.

As a leading enterprise in the field of precision oncology diagnostics, from ROS1 to AiHuiJian^®, Weihuijian^®Amoy Diagnostics proactively anchors its strategy to clinical needs by developing high-quality companion diagnostic reagents, comprehensively supporting the clinical research of major targeted therapies both domestically and internationally, and earning high recognition from partners. Johnson & Johnson’s selection of Amoy Diagnostics as its companion diagnostics partner for its oncology portfolio demonstrates trust and affirmation in Amoy’s brand and products, highlighting the strong competitiveness of Amoy Diagnostics’ comprehensive companion diagnostic solutions powered by its multi-technology platforms.

Informed Treatment: Making Precision Oncology More Precise. Driven by this visionary goal, Amoy Diagnostics and Johnson & Johnson have formed a strategic partnership to advance together. Both parties look forward to accelerating the market launch of Johnson & Johnson’s novel targeted therapies, supported by Amoy Diagnostics’ companion diagnostics, thereby benefiting more cancer patients.

About Johnson & Johnson（Johnson & Johnson）

Johnson & Johnson, founded in 1886, is a renowned American multinational corporation dedicated to the development of medical devices, pharmaceuticals, and consumer care products. Its common stock is a component of the Dow Jones Industrial Average, and the company ranked 37th on the 2018 Fortune 500 list by total revenue.